Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) – Pipeline Review, H2 2016’, provides in depth analysis on Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) targeted pipeline therapeutics.

The report provides comprehensive information on the Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2)

The report reviews Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects

The report assesses Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 2.7.10.2) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Advenchen Laboratories LLC

Athenex Inc

Basilea Pharmaceutica Ltd

Pfizer Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC

2.7.10.2) Overview 7

Therapeutics Development 8

Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC

2.7.10.2) - Products under Development by Stage of Development 8

Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC

2.7.10.2) - Products under Development by Therapy Area 9

Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC

2.7.10.2) - Products under Development by Indication 10

Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC

2.7.10.2) - Pipeline Products Glance 12

Late Stage Products 12

Early Stage Products 13

Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC

2.7.10.2) - Products under Development by Companies 14

Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC

2.7.10.2) - Products under Development by Universities/Institutes 17

Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC

2.7.10.2) - Therapeutics Assessment 19

Assessment by Monotherapy/Combination Products 19

Assessment by Mechanism of Action 20

Assessment by Route of Administration 21

Assessment by Molecule Type 23

Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC

2.7.10.2) - Companies Involved in Therapeutics Development 25

Advenchen Laboratories LLC 25

Athenex Inc 26

Basilea Pharmaceutica Ltd 27

Pfizer Inc 28

Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC

2.7.10.2) - Drug Profiles 29

apatinib - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

bosutinib - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

CCT-196969 - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

CCT-241161 - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

eCF-506 - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

KX-01 - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

KX-02 - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

PP-1 - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

Small Molecule to Inhibit c-Src Tyrosine Kinase for Oncology - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

Small Molecules to Inhibit Src Kinase for Oncology - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

Small Molecules to Inhibit Src Tyrosine Kinase for Colon Cancer - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

Synthetic Peptide to Inhibit Src Tyrosine Kinase for Prostate Cancer - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

UM-164 - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC

2.7.10.2) - Dormant Projects 49

Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC

2.7.10.2) - Discontinued Products 50

Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC

2.7.10.2) - Featured News & Press Releases 51

Oct 18, 2016: Athenex announces Xiangxue Pharmaceuticals, its KX-02 development partner in China, has achieved a regulatory milestone in that territory 51

Aug 24, 2016: NICE approves new cancer drug bosutinib for routine NHS use 51

Jul 26, 2016: LSK BioPharma Announces Successful Outcome from End-of-Phase 2 meeting with FDA 52

Jul 07, 2016: NICE approves first drug from old Cancer Drugs Fund 52

Jun 08, 2016: New compound shows potential for triple-negative breast cancer 53

May 23, 2016: Breast cancer drug discovery offers hope of new treatments 54

Sep 15, 2015: Avillion Announces Completion of Enrolment in Phase III BFORE Trial to Assess BOSULIF (bosutinib) as First-Line Treatment for Patients with Chronic Myelogenous Leukemia 55

Feb 18, 2015: Particle Sciences Manufactures Clinical Supplies for Kinex's Glioblastoma Therapeutic 55

Jan 20, 2015: Kinex Pharmaceuticals Announces First Patient Dosed with KX2-391 Ointment for Actinic Keratosis in a Phase 1 Clinical Study 56

Dec 24, 2014: Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 56

Dec 09, 2014: Pfizer Demonstrates New Data On BOSULIF at ASH 2014 57

Aug 11, 2014: Avillion Announces Dosing of First Patients in Phase 3 BFORE Trial to Assess BOSULIF (bosutinib) as First-Line Treatment for Patients with Chronic Myelogenous Leukemia 57

Jul 24, 2014: Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 58

Mar 30, 2014: Atlantic Research Group Client Kinex Pharmaceuticals Initiate Phase I Glioblastoma trial 59

Jan 09, 2014: Avillion Partners with Pfizer to Co-develop BOSULIF (bosutinib) as First-Line Treatment for Patients with Chronic Myelogenous Leukemia 59

Appendix 61

Methodology 61

Coverage 61

Secondary Research 61

Primary Research 61

Expert Panel Validation 61

Contact Us 61

Disclaimer 62

List of Tables

List of Tables

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Indication, H2 2016 11

Comparative Analysis by Late Stage Development, H2 2016 12

Comparative Analysis by Early Stage Products, H2 2016 13

Number of Products under Development by Companies, H2 2016 14

Products under Development by Companies, H2 2016 15

Products under Development by Companies, H2 2016 (Contd..1) 16

Number of Products under Investigation by Universities/Institutes, H2 2016 17

Products under Investigation by Universities/Institutes, H2 2016 18

Assessment by Monotherapy/Combination Products, H2 2016 19

Number of Products by Stage and Mechanism of Action, H2 2016 20

Number of Products by Stage and Route of Administration, H2 2016 22

Number of Products by Stage and Molecule Type, H2 2016 24

Pipeline by Advenchen Laboratories LLC, H2 2016 25

Pipeline by Athenex Inc, H2 2016 26

Pipeline by Basilea Pharmaceutica Ltd, H2 2016 27

Pipeline by Pfizer Inc, H2 2016 28

Dormant Projects, H2 2016 49

Discontinued Products, H2 2016 50

List of Figures

List of Figures

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Top 10 Indication, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 12

Comparative Analysis by Early Stage Products, H2 2016 13

Assessment by Monotherapy/Combination Products, H2 2016 19

Number of Products by Stage and Mechanism of Actions, H2 2016 20

Number of Products by Routes of Administration, H2 2016 21

Number of Products by Stage and Routes of Administration, H2 2016 21

Number of Products by Molecule Types, H2 2016 23

Number of Products by Stage and Molecule Type, H2 2016 23

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports